195 related articles for article (PubMed ID: 21385922)
1. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
Muldoon LL; Lewin SJ; Dósa E; Kraemer DF; Pagel MA; Doolittle ND; Neuwelt EA
Clin Cancer Res; 2011 Apr; 17(8):2207-15. PubMed ID: 21385922
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma.
Jahnke K; Muldoon LL; Varallyay CG; Lewin SJ; Brown RD; Kraemer DF; Soussain C; Neuwelt EA
Neuro Oncol; 2009 Oct; 11(5):503-13. PubMed ID: 19158414
[TBL] [Abstract][Full Text] [Related]
3. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
4. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
5. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
[TBL] [Abstract][Full Text] [Related]
6. Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
Miyake Y; Okoshi Y; Machino T; Chiba S
Int J Hematol; 2010 Oct; 92(3):474-80. PubMed ID: 20820968
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
[TBL] [Abstract][Full Text] [Related]
8. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
[TBL] [Abstract][Full Text] [Related]
9. Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption.
Macnealy MW; Newton HB; McGregor JM; Bell SD; Ray Chaudhury A; Slone HW; Bourekas EC
J Neurooncol; 2008 Dec; 90(3):329-33. PubMed ID: 18758913
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.
Chamberlain MC; Johnston SK
Neuro Oncol; 2010 Jul; 12(7):736-44. PubMed ID: 20511181
[TBL] [Abstract][Full Text] [Related]
11. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers.
Kroll RA; Pagel MA; Muldoon LL; Roman-Goldstein S; Fiamengo SA; Neuwelt EA
Neurosurgery; 1998 Oct; 43(4):879-86; discussion 886-9. PubMed ID: 9766316
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
13. High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma.
Masaki Y; Miki M; Sun Y; Nakamura T; Iwao H; Nakajima A; Kurose N; Sakai T; Jin ZX; Sawaki T; Kawanami T; Fujita Y; Tanaka M; Fukushima T; Hirose Y; Umehara H
Int J Hematol; 2011 Jun; 93(6):720-726. PubMed ID: 21573892
[TBL] [Abstract][Full Text] [Related]
14. Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.
Doolittle ND; Muldoon LL; Culp AY; Neuwelt EA
Adv Pharmacol; 2014; 71():203-43. PubMed ID: 25307218
[TBL] [Abstract][Full Text] [Related]
15. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma.
Montraveta A; Xargay-Torrent S; López-Guerra M; Rosich L; Pérez-Galán P; Salaverria I; Beà S; Kalko SG; de Frias M; Campàs C; Roué G; Colomer D
Oncotarget; 2014 Feb; 5(3):726-39. PubMed ID: 24519895
[TBL] [Abstract][Full Text] [Related]
17. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
[TBL] [Abstract][Full Text] [Related]
18. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
Gopal AK; Press OW; Wilbur SM; Maloney DG; Pagel JM
Blood; 2008 Aug; 112(3):830-5. PubMed ID: 18502830
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Enting RH; Demopoulos A; DeAngelis LM; Abrey LE
Neurology; 2004 Sep; 63(5):901-3. PubMed ID: 15365145
[TBL] [Abstract][Full Text] [Related]
20. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
